Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
Protara Therapeutics, Inc. (Nasdaq: TARA) will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protara Therapeutics, Inc. (Nasdaq: TARA) will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation will be available on January 10 at 7:00 am ET through the Company's website. Protara focuses on developing therapies for cancer and rare diseases, featuring its lead program TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations. Additionally, IV Choline Chloride targets intestinal failure-associated liver disease. The presentation will be archived for 90 days on their website.
Details
News Market Reaction – TARA
The recorded move for TARA in the trading session of this news was -3.04%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022.
The prerecorded presentation will become available on Monday, January 10, 2022 at 7:00am ET and can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived on the Company’s website for 90 days following the presentation.
About Protara Therapeutics, Inc.
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.